BRAF, PIK3CA, and HER2 Oncogenic Alterations According to KRAS Mutation Status in Advanced Colorectal Cancers with Distant Metastasis.
Anti-EGFR antibody-based treatment is an important therapeutic strategy for advanced colorectal cancer (CRC); despite this, several mutations--including KRAS, BRAF, and PIK3CA mutations, and HER2 amplification--are associated with the mechanisms underlying the development of resistance to anti-EGFR...
Main Authors: | Soo Kyung Nam, Sumi Yun, Jiwon Koh, Yoonjin Kwak, An Na Seo, Kyoung Un Park, Duck-Woo Kim, Sung-Bum Kang, Woo Ho Kim, Hye Seung Lee |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2016-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4798471?pdf=render |
Similar Items
-
KRAS/NRAS Mutations Associated with Distant Metastasis and BRAF/PIK3CA Mutations Associated with Poor Tumor Differentiation in Colorectal Cancer
by: Zeng J, et al.
Published: (2023-09-01) -
Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2–3 randomised trial
by: Adams, R, et al.
Published: (2017) -
Prevalence of KRAS, PIK3CA, BRAF and AXIN2 gene mutations in colorectal cancer and their relationship with dental agenesis: a systematic review
by: Francisco Sir-Mendoza, et al.
Published: (2021-12-01) -
Significance of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer patients receiving Bevacizumab: a single institution experience
by: Edita Baltruškevičienė, et al.
Published: (2016-04-01) -
Oncogenic KRAS: Signaling and Drug Resistance
by: Hyeon Jin Kim, et al.
Published: (2021-11-01)